Enfortumab vedotin + Pembrolizumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle Invasive Bladder Urothelial Carcinoma
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Trial Timeline
Apr 7, 2025 → Nov 1, 2029
NCT ID
NCT06809140About Enfortumab vedotin + Pembrolizumab
Enfortumab vedotin + Pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Muscle Invasive Bladder Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06809140. Target conditions include Muscle Invasive Bladder Urothelial Carcinoma.
What happened to similar drugs?
2 of 20 similar drugs in Muscle Invasive Bladder Urothelial Carcinoma were approved
Approved (2) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07475806 | Phase 2 | Recruiting |
| NCT06906822 | Phase 2 | Recruiting |
| NCT06809140 | Phase 2 | Recruiting |
| NCT06470282 | Phase 1/2 | Recruiting |
| NCT05756569 | Phase 2 | Recruiting |
| NCT05239624 | Phase 2 | Recruiting |
| NCT04225117 | Phase 2 | Active |
Competing Products
20 competing products in Muscle Invasive Bladder Urothelial Carcinoma